Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Eisai announced results from the Phase 3 LEAP-015 trial evaluating KEYTR...
Pfizer Inc. (NYSE: PFE) announced positive results from the Phase 3 BREAKWATER trial evaluating BRAFTOVI® (encorafenib) in combination ...
CG Pharmaceuticals (CG Pharma), a clinical biopharmaceutical company located in the San Francisco Bay Area, was established as an independent entity i...
AbbVie (NYSE: ABBV) and Neomorph, Inc. announced a collaboration and option-to-license agreement to develop novel molecular glue degraders for multiple tar...
AstraZeneca, a global pharmaceutical company focused on developing life changing medicines, announced a C$820 million (US$570m) investment in Canada,...
GC Cell, a leading cell and gene therapy company, announced the successful completion of its first thought leadership symposium in Jakarta, Indonesia....
Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is excited to announce that the prestigious medical journal Nature Medicine published the results of ...
Beckman Coulter Life Sciences, a global leader in laboratory automation and innovation, along with the Indiana University School of Medicine, have been a...
Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies fo...
Antennova, a clinical-stage biotech company focused on oncology announced the presentation of latest data from its Phase I/II CLINCH s...
MediBeacon Inc. today announced the U.S. Food and Drug Administration (FDA) has approved the MediBeacon® TGFR for the assessment of kidney fu...
IMPACT Therapeutics ("IMPACT"), a biopharmaceutical company focusing on the discovery and development of targeted anti-cancer therapeutics based on s...
University of California, San Francisco (UCSF) Department of Radiology & Biomedical Imaging and GE HealthCare announced the launch of a Care Inno...
Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotech developing RNA interference (RNA...
© 2025 Biopharma Boardroom. All Rights Reserved.
